Company intelligence / Profile preview

Shape Pharmaceuticals

Cambridge, MA, United Statesshapetx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Shape Pharmaceuticals developed a tissue-targeted HDAC inhibitor in a topical gel formulation for early-stage cutaneous T-cell lymphoma. The company reported encouraging clinical data with notable response rates and early onset of action prior to its acquisition by TetraLogic. The lead program was expected to enter Phase 2 trials post-acquisition.

Therapeutic areas: Oncology
Modalities: Small molecules (specifically HDAC inhibitors)
Industry: Biotech

Drug pipeline

1 asset

RNAfix

Pre-clinical

Indications: Rett syndrome, Genetic disorders

Beyond the preview

Go deeper on Shape Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shape Pharmaceuticals.

Explore the full profile